We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bartosiak: Trading Mallinckrodt's (MNK) Earnings with Options
Read MoreHide Full Article
On Tuesday, February 7th, Mallinckrodt will release its fourth quarter earnings results before the bell. The company is a Zacks Rank 5 (Strong Sell), and have a Value, Growth, and Momentum score of A.
Dave will look at Mallinckrodt’s past earnings, take a look at what is currently going on with the company, and give us his thoughts on their upcoming earnings announcement.
Furthermore, Dave will uncover some potential options trades for investors looking to make a play on Mallinckrodt ahead of earnings.
Mallinckrodt in Focus
Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.
Mallinckrodt is expected to report earnings at $1.84 per share according to the Zacks Consensus Estimate. Last quarter they beat earnings expectations by 3.03%. They reported earnings at $2.04 per share, beating their estimate of $1.98. They have an average earnings surprise of 11.20%.
Mallinckrodt PLC Price, Consensus and EPS Surprise
How should investors play Mallinckrodt ahead of their earnings report? For insights on the best options trades, then tune in at 9:00am tomorrow to see David’s thoughts.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
Due to inactivity, you will be signed out in approximately:
Image: Bigstock
Bartosiak: Trading Mallinckrodt's (MNK) Earnings with Options
On Tuesday, February 7th, Mallinckrodt will release its fourth quarter earnings results before the bell. The company is a Zacks Rank 5 (Strong Sell), and have a Value, Growth, and Momentum score of A.
Dave will look at Mallinckrodt’s past earnings, take a look at what is currently going on with the company, and give us his thoughts on their upcoming earnings announcement.
Furthermore, Dave will uncover some potential options trades for investors looking to make a play on Mallinckrodt ahead of earnings.
Mallinckrodt in Focus
Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.
Mallinckrodt is expected to report earnings at $1.84 per share according to the Zacks Consensus Estimate. Last quarter they beat earnings expectations by 3.03%. They reported earnings at $2.04 per share, beating their estimate of $1.98. They have an average earnings surprise of 11.20%.
Mallinckrodt PLC Price, Consensus and EPS Surprise
Mallinckrodt PLC Price, Consensus and EPS Surprise | Mallinckrodt PLC Quote
Bottom Line
How should investors play Mallinckrodt ahead of their earnings report? For insights on the best options trades, then tune in at 9:00am tomorrow to see David’s thoughts.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>